SLNO

Soleno Therapeutics Inc

Add to Watchlist

Advanced Chart

86.470

-1.56(-1.772%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

88.980

Open

88.320

VWAP

87.06

Vol

790.65K

Mkt Cap

4.49B

Low

86.220

Amount

68.83M

EV/EBITDA(TTM)

Total Shares

36.86M

4.25B

EV/OCF(TTM)

P/S(TTM)

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

9 Analyst Rating

25.15% Upside

Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 108.22 USD with a low forecast of 81.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

25.15% Upside

Current: 86.470

Low

81.00

Averages

108.22

High

145.00

25.15% Upside

Current: 86.470

Low

81.00

Averages

108.22

High

145.00

Baird

Brian Skorney

Outperform

maintain

$105 -> $121

2025-07-11

Reason

Baird

Brian Skorney

Price Target

$105 -> $121

2025-07-11

maintain

Outperform

Reason

Baird analyst Brian Skorney raised the firm's price target on Soleno Therapeutics to $121 from $105 and keeps an Outperform rating on the shares. The firm updated its model after Q2 Vykat sales blew out expectations.

Stifel

Buy

maintain

$108 -> $118

2025-07-08

Reason

Stifel

Price Target

$108 -> $118

2025-07-08

maintain

Buy

Reason

Stifel raised the firm's price target on Soleno Therapeutics to $118 from $108 and keeps a Buy rating on the shares after having conducted a survey of 20 physicians. The firm's survey work found demand is "significant" and widespread, according to the analyst, who calls the results "highly favorable" for Vykat and broadly supportive of the Soleno bull case. The firm came away from its work more confident in its view that Vykat should track with other "very strong" initial rare disease drug launches and it now models about $2.5B in peak sales.

Stifel

Buy

maintain

$108 -> $115

2025-07-08

Reason

Stifel

Price Target

$108 -> $115

2025-07-08

maintain

Buy

Reason

Stifel raised the firm's price target on Soleno Therapeutics to $115 from $108 and keeps a Buy rating on the shares after having conducted a survey of 20 physicians. The firm's survey work found demand is "significant" and widespread, according to the analyst, who calls the results "highly favorable" for Vykat and broadly supportive of the Soleno bull case. The firm came away from its work more confident in its view that Vykat should track with other "very strong" initial rare disease drug launches and it now models about $2.5B in peak sales.

TD Cowen

Tyler Van Buren

Buy

initiated

$110

2025-06-23

Reason

TD Cowen

Tyler Van Buren

Price Target

$110

2025-06-23

initiated

Buy

Reason

Baird

Brian Skorney

Outperform

maintain

$102 -> $105

2025-05-08

Reason

Baird

Brian Skorney

Price Target

$102 -> $105

2025-05-08

maintain

Outperform

Reason

Baird analyst Brian Skorney raised the firm's price target on Soleno Therapeutics to $105 from $102 and keeps an Outperform rating on the shares. The firm said 268 start forms in one month is a very good beginning to its launch.

Guggenheim

Buy

upgrade

$81 -> $97

2025-05-08

Reason

Guggenheim

Price Target

$81 -> $97

2025-05-08

upgrade

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Soleno Therapeutics Inc (SLNO.O) is -87.42, compared to its 5-year average forward P/E of -10.08. For a more detailed relative valuation and DCF analysis to assess Soleno Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.08

Current PE

-87.42

Overvalued PE

2.42

Undervalued PE

-22.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

72.75

Current PS

27.96

Overvalued PS

302.60

Undervalued PS

-157.09